L1-specific protection from tumor challenge elicited by HPV16 virus- like particles

Virology

Volumn 250, Issue 2, 1998, Pages 371-376

  De Bruijn, Marloes L H ^a   Greenstone, Heather L ^b   Vermeulen, Hans ^a   Melief, Cornelis J M ^a   Lowy, Douglas R ^b   Schiller, John T ^b   Kast, W Martin ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; MONOCLONAL ANTIBODY; RNA;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; IMMUNE RESPONSE; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VIRUS CELL TRANSFORMATION; VIRUS GENOME; VIRUS PARTICLE; WART VIRUS;

ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0032566921     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9372     Document Type: Article

References (23)

1. Brown M. G., Driscoll J., Monaco J. J. Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinases) complexes. Nature. 353:1991;355-357.
2. Christensen N. D., Dillner J., Eklund C., Carter J. J., Wipf G. C., Reed C. A., Cladel N. M., Galloway D. A. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology. 223:1996;174-184.
3. Dialynas D. P., Quan Z. S., Wall K. A., Pierres A., Quintans J., Koken M. R., Pierres M., Fitch F. W. Characterization of the murine T cell surface molecule designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131:1983;2445-2451.
4. Dupuy C., Buzoni-Gatel D., Touze A., Le Cann P., Bout D., Coursaget P. Cell mediated immunity induced in mice by HPV16 L1 virus-like particles. Micro. Pathol. 22:1997;219-225.
5. Feltkamp M. C., Smits H. L., Vierboom M. P. M., Minnaar R. P., De Jongh B. M., Drijfhout J. W., Ter Schegget J., Melief C. J., Kast W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:1993;2242-2249.
6. Feltkamp M. C. W., Vreugdenhil G. R., Vierboom M. P. M., Ras E., Van der Burg S. H., Ter Schegget J., Melief C. J. M., Kast W. M. CTL raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25:1995;2638-2642.
7. Glynne R., Powis S. H., Beck S., Kelly A., Kerr L. A., Trowsdale J. A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature. 353:1991;357-360.
8. Greenstone H. L., Nieland J. D., De Visser K. E., De Bruijn M. L. H., Kirnbauer R., Roden R. B. S., Lowy D. R., Kast W. M., Schiller J. T. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA. 95:1998;1800-1805.
9. Kast W. M., Offringa R., Peters P. J., Voordouw A. C., Meloen R. H., Van der Eb A. J., Melief C. J. M. Eradication of adenovirus E1-induced tumors by E1A specific cytotoxic T lymphocytes. Cell. 59:1989;603-614.
10. Kast W. M., Feltkamp M. C. W., Ressing M. E., Vierboom M. P. M., Brandt R. M. P., Melief C. J. M. Cellular immunity against human papillomavirus associated cervical cancer. Semin. Virol. 7:1996;117-123.
11. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA. 89:1992;12180-12184.
12. Kirnbauer R., Taub J., Greenstone H., Roden R. B. S., Durst M., Gissmann L., Lowy D. R., Schiller J. T. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:1993;6929-6936.
13. Kovacsovics-Bankowski M., Clark K., Benacerraf B., Rock K. L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA. 90:1993;4942-4946.
14. Lin K.-Y., Guarnieri F. G., Staveley-O'Carroll K. F., Levitsky H. I., August J. T., Pardoll D. M., Wu T.-C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
15. Muller M., Zhou J., Reed T. D., Rittmuller C., Burger A., Gabelsberger J., Braspenning J., Gissmann L. Chimeric papillomavirus-like particles. Virology. 234:1997;93-111.
16. Roden R. B. S., Hubbert N. L., Kirnbauer R., Christensen N. D., Lowy D. R., Schiller J. T. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 70:1996;3298-3301.
17. Sarmiento M., Glasebrook A. L., Fitch F. W. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol. 125:1980;2665-2672.
18. Schiller J. T., Okun M. Papillomavirus vaccines: current status and future prospects. Adv. Dermat. 11:1996;355-380.
19. Schoenberger S. P., Jonges L. E., Mooijaart R. J. D., Hartgers F., Toes R. E. M., Kast W. M., Melief C. J. M., Offringa R. B7-1 expression converts a highly antigenic, but non-immunogenic embryonic fibroblast into a potent APC capable of direct CTL priming in vivo. Cancer Res. 58:1998;3094-3100.
20. Stoler M. H., Rhodes M. H., Witbeck A., Wolinsky S. M., Chow L. T., Broker T. R. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23:1992;117-128.
21. Taichman L. B., LaPorta R. F. The expression of papillomaviruses in human epithelial cells. The Papovaviridae: Volume 2. The Papillomaviruses. 1987;Plenum Press, New York. p. 109-139.
22. Toes R. E. M., Offringa R., Blom R. J. J., Brandt R. M. P., Van der Eb J., Melief C. J. M., Kast W. M. An Ad5 E1B-encoded CTL epitope mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J. Immunol. 154:1995;3396-3405.
23. Zhou J., McIndoe A., Davies H., Sun X. Y., Crawford L. The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia virus expressing human papillomavirus type 16 L1. Virology. 181:1991;203-210.